Display options
Cite
Umbricht D, Javitt D, Novak G, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999;2(4):299-304doi: 10.1017/S1461145799001595.
Umbricht, D., Javitt, D., Novak, G., Bates, J., Pollack, S., Lieberman, J., & Kane, J. (1999). Effects of risperidone on auditory event-related potentials in schizophrenia. The international journal of neuropsychopharmacology, 2(4), 299-304. https://doi.org/10.1017/S1461145799001595
Umbricht, Daniel, et al. "Effects of risperidone on auditory event-related potentials in schizophrenia." The international journal of neuropsychopharmacology vol. 2,4 (1999): 299-304. doi: https://doi.org/10.1017/S1461145799001595
Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999 Dec;2(4):299-304. doi: 10.1017/S1461145799001595. PMID: 11285146.
Copy Download .nbib Format: NLM
Share it on

Int J Neuropsychopharmacol. 1999 Dec;2(4):299-304. doi: 10.1017/S1461145799001595.

Effects of risperidone on auditory event-related potentials in schizophrenia.

The international journal of neuropsychopharmacology

Daniel Umbricht, Daniel Javitt, Gerald Novak, John Bates, Simcha Pollack, Jeffrey Lieberman, John Kane

Affiliations

  1. Research Department, Psychiatric University Hospital, 8029 Zurich, Switzerland.

PMID: 11285146 DOI: 10.1017/S1461145799001595

Abstract

Schizophrenia is associated with cognitive deficits for which treatments remain elusive. The effects of risperidone (an antipsychotic differing in some of its pharmacological properties from typical agents) on cognitive deficits have not been extensively investigated. Mismatch negativity (MMN), N2 and P3 are cognitive event-related potentials that index preattentive (MMN) and attention-dependent information processing (N2, P3) and provide a measure of cognitive deficits in schizophrenia. The effects of risperidone treatment on MMN, N2 and P3 generation in chronic schizophrenic patients were investigated in an open- label, uncontrolled study. Risperidone treatment significantly reduced psychotic symptoms. It was associated with a decrease of peak latencies, particularly pronounced for P3. However, it did not significantly affect abnormal MMNor P3 amplitudes. The results suggest an effect of risperidone on processing speed, particularly in attention-dependent tasks. These results are in agreement with findings in recent studies on the cognitive effects of risperidone.

Publication Types